Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...

Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of ...

Starlink launches its cheapest plan yet: $40/month for 100Mbps and unlimited data. Find out the key catches and limited US ...

Anthropic announces $50 billion investment in building AI data centers in the US. These centers will go live in Texas and New ...

CT analysis of tablet microstructure reveals critical insights into disintegration and dissolution, driving improvements in ...

Priced around $250, this tablet offers a big screen and powerful speakers for enjoying videos, audio, books, and light gaming ...

The result: planning friction, shallow talent pools, and facilities positioned as impositions rather than enablers. Operators ...

One UI 8.5 could introduce Adaptive data saver for Galaxy phones to reduce data usage on social media apps without degrading ...

According to Gilead, a single-tablet regimen could provide a new medication option with convenient dosing for people living with HIV by lowering pill burden. Participants in the late-stage study were ...

The Tablet Coating Market is driven by increased demand for advanced drug delivery systems, growth in pharmaceutical and ...

FBI Director Kash Patel announced at the White House on Wednesday (November 12) that China has agreed on a plan to stop ...